Breaking News

DSM, Chemtrix In Continuous Flow Chemistry Pact

February 20, 2013

Aims to provide new processes for API development and manufacture

DSM Pharmaceutical Products and Chemtrix BV have signed a collaboration agreement in the field of continuous flow chemistry to provide equipment, development and manufacturing services to the pharmaceutical industry. The agreement combines the chemistry expertise of both companies and aims to provide new technologies and processes for the development and manufacture of APIs to increase sustainability, reduce energy consumption and provide benefits for cost-of-goods.
Chemtrix will contribute its ready-to-use lab and kilo-scale micro reactors, as well as reactor and process design for industrial reactors, and DSM will employ its expertise in drug synthesis route development, scale-up and implementation of continuous flow processes for manufacturing. Initially the collaboration will offer an Industrial Flow Process Development package to clients to provide custom, scalable flow chemistry solutions, which covers all phases of process design, from scanning chemistries, chemistry development, route scouting, equipment design and scale-up.
Alexander Wessels, president and chief executive officer of DSM Pharmaceutical Products, said, "Working with Chemtrix underlines the further advancement of DSM's stated strategy toward strategic partnerships to excel in providing new customer solutions. DSM is a global leader in cGMP continuous flow chemistry manufacturing, with a commitment to the future of pharmaceutical manufacturing in a sustainable manner." 
Hugo Delissen, chief executive officer of Chemtrix BV, said, "Together with DSM we are the most complete flow chemistry partner for pharmaceutical and fine chemical companies. Delivering a complete package of equipment and services based on our joint knowledge ranging from lab (milligrams) to production (ton) scale, ensures the delivery of the best possible solutions for our joint customers."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.